In forty-eight consecutive patients undergoing explants of transcatheter aortic valve replacement (TAVR) at a single center between 2011 and 2021, at a median of 2.3 years after TAVR, the most common indications for surgery were nonstructural valve dysfunction (patient-prosthesis mismatch or paravalvular leak) in 35 percent, structural valve deterior
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR (TAVI)
June 29, 2023
Recently, a minimal approach to transcatheter valve replacement using only local anesthesia has been used to promote a faster procedure and recovery time. With this lack of general anesthesia, however, comes more anxiety and the possibility of pain for patients.
June 29, 2023
Transcatheter aortic valve implantation (TAVI) is now a standard procedure for the treatment of symptomatic aortic valve stenosis in many patients.
February 23, 2023
A new study found that patients who undergo TAVR with concomitant chronic total occlusion lesions are more likely to experience complications from the procedure, but they do not have a higher risk of mortality. The results suggest that if a patient is otherwise a candidate for TAVR, their CTO status should not exclude them from the surgery.
January 27, 2023
A novel self-expanding TAVR valve has been successfully implanted in ten patients, as reported by a research team in China. The new device is made of a self-expanding nitinol stent with three valve leaflets of bovine pericardial, reduces the risk of coronary obstruction, and is completely retrievable and repositionable.
January 12, 2023
INTEGRITTY, a group dedicated the appraisal of evidence to support optimized patient management, published a paper highlighting concerns surrounding major TAVR versus SAVR studies. While their findings do not aim to directly discredit the studies, they do raise questions about the integrity of their methodology.
December 21, 2022
A comparative study between five types of transcatheter heart valves found that although adverse outcome rates are low among all devices, some differences do stand out.
September 2, 2022
In the past, there has not been an accurate way to calculate mortality risk for patients with atrial fibrillation (AF) who have undergone a successful transcatheter aortic valve implantation (TAVI) and have been discharged home.
June 4, 2021
On May 25, 2021, Dr. David Heimansohn successfully performed the first surgical implantation of biopolymer Tria™ heart valve in a patient with mitral valve disease at Ascension St. Vincent Hospital, Indianapolis, IN.
February 21, 2021
In this article, Thourani et al present the International Society for Minimally Invasive Cardiothoracic Surgery Expert Consensus Statement on transcatheter and surgical aortic valve replacement in low- and intermediate-risk patients: A meta-analysis of randomized and propensity-matched studies.